| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jing-Ya Yin, Tian-Yuan Yang, Bing-Qing Yang, Chen-Xue Hou, Jun-Nan Li, Yue Li and Qi Wang |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82170591 |
| Natural Science Foundation of Beijing |
7222097 |
|
| Corresponding Author |
Qi Wang, MD, PhD, Associate Professor, Associate Research Scientist, Chief Physician, Doctor, Doctor, Teacher, Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wangqidl04@ccmu.edu.cn |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; High-risk metabolic dysfunction-associated steatohepatitis; Non-invasive models; Liver biopsy; Diagnostic value |
| Core Tip |
Patients with high-risk metabolic dysfunction-associated steatohepatitis (MASH) are more likely to develop cirrhosis or hepatocellular carcinoma. Early diagnosis, particularly without a liver biopsy, presents significant challenges. Exploring non-invasive models may increase detection efficiency. Although metabolic dysfunction-associated steatotic liver disease originates from non-alcoholic fatty liver disease, patient cohorts do not entirely overlap. Our study validated the concordance between these two distinct populations. To determine the effective replacement of liver biopsy with non-invasive models for diagnosing high-risk MASH, we utilized existing data to select seven diagnostic methods and assessed their diagnostic value for high-risk MASH. |
| Publish Date |
2024-05-11 10:58 |
| Citation |
<p>Yin JY, Yang TY, Yang BQ, Hou CX, Li JN, Li Y, Wang Q. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis. <i>World J Gastroenterol</i> 2024; 30(18): 2440-2453</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i18/2440.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i18.2440 |
